Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

Do you have cardiomyopathy that has led to moderate or severe mitral regurgitation? This study is exploring the best surgical technique to repair mitral regurgitation by comparing two procedures called undersizing mitral annuloplasty (UMA) and papillary muscle approximation (PMA). A UMA is a common procedure that involves implanting a prosthetic ring onto the mitral valve to stop the valve from leaking. A PMA is a newer technique in which a suture draws together the two muscles that connect the mitral valve to the heart muscle prior to performing UMA. To participate in this study, you must be 18 years old or older and have never had a mitral valve repair procedure. This study takes place in Atlanta, Georgia.